DE2254043C2 - LH-releasing hormone for nasal application - Google Patents
LH-releasing hormone for nasal applicationInfo
- Publication number
- DE2254043C2 DE2254043C2 DE2254043A DE2254043A DE2254043C2 DE 2254043 C2 DE2254043 C2 DE 2254043C2 DE 2254043 A DE2254043 A DE 2254043A DE 2254043 A DE2254043 A DE 2254043A DE 2254043 C2 DE2254043 C2 DE 2254043C2
- Authority
- DE
- Germany
- Prior art keywords
- aqueous
- preparation
- preparations
- nasal
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
Description
, ι , ι
33
se versehen werden. Beispiel 7se are provided. Example 7
Gelees werden z. B. in Kunststoff tuben oder in innenJellies are z. B. in plastic tubes or inside
schutzlackierten Tuben aus Reinaluminium oder Rein- In 91 destilliertem Wasser werden ohne zu erwärmenProtective coated tubes made of pure aluminum or pure In 91 distilled water are used without heating
zinn gefüllt Sinnvoll sind auch kleine Kunststoffbehäl- 35,44 g Citronensäure, 32,76 g Na2HPO* 400 g Sorbittin-filled Small plastic containers are also useful - 35.44 g citric acid, 32.76 g Na 2 HPO * 400 g sorbitol
ter z. B. aus Polyäthylen zur Aufnahme von Einzeldosen 5 und 40 g Chlorbutanol gelöst Dann werden 400 g LH-ter z. B. made of polyethylene to accommodate single doses of 5 and 40 g of chlorobutanol dissolved Then 400 g of LH-
der Lösungen oder des Gelees. Die erfindungsgemäßen RH gelöst Mit destilliertem Wasser wird auf 101 aufge-solutions or jelly. The RH according to the invention dissolved with distilled water is made up to 101
Zubereitungen enthalten ArzneimitteL Sie werden bei füllt und die Lösung filtriert Mensch und Tier angewendet und bewirken bei Hypo-Preparations contain medicinal products. When they are filled, the solution is filtered Applied to humans and animals and cause hypo-
thalarous-Insuffizienz oder bei hypothalamisch-hypo- Beispiel 8 physären Störungen die Ausschüttung von luteinisieren-thalarous insufficiency or with hypothalamic-hypo- Example 8 physical disturbances the distribution of luteinizing
dem Hormon und auch von follikelstimulierendem Hör- In 61 destilliertem Wasser von ca. 50° C werden 200 gthe hormone and also follicle-stimulating hearing In 61 distilled water at approx. 50 ° C are 200 g
mon, werden also beim weiblichen Organismus zur Her- Methylcellulose mit einem Durchschnittssubstitutions-mon, so in the female organism they become Her- methylcellulose with an average substitution
beiführung einer Ovulation zu einem bestimmten Zeit- grad von ca. 1,5 und einer Viskosität von 2700 bisinduction of ovulation at a certain time of approx. 1.5 and a viscosity of 2700 to
punkt, beim männlichen Organismus z. B. zur Behebung 4000 cP (z. B. Tylose·) suspendiert Man läßt die Sus-point, in the male organism z. B. to remedy 4000 cP (e.g. Tylose ·) suspended.
von Störungen der Spermatogenese angewandt , :s pension unter Rühren auf Raumtemperatur abkühlen.applied to disorders of spermatogenesis : cool the pension to room temperature while stirring.
Dabei quillt die Methylcellulose auf. In 31 destilliertemThe methyl cellulose swells in the process. In 31 distilled
Beispiel 1 Wasser werden 400 ml n-Essigsäure, 282 ml n-Natron-Example 1 400 ml of n-acetic acid, 282 ml of n-sodium
lauge, 350 g Mannit, 500 mg Benzalkoniumchlorid undliquor, 350 g mannitol, 500 mg benzalkonium chloride and
In 81 destilliertem Wasser werden ohne zu erwärmen zum Schluß 5 g LH-RH gelöst Die Lösung wird filtriertFinally, 5 g of LH-RH are dissolved in 81 distilled water without heating. The solution is filtered
31,2 g NaH2PO4 - 2 H2O, 66,29 g Na2HPO4,25 g Natri- 20 und mit der Methylcellulose-Lösung vereinigt Mit de-31.2 g NaH 2 PO 4 - 2 H 2 O, 66.29 g Na 2 HPO 4 , 25 g sodium 20 and combined with the methyl cellulose solution.
umchlorid »ri4 100 g Benzylalkohol gelöst Dann wird stilliertem Wasser wird auf 10 laufgefüllt 500 g Polyvinylpyrolidon mit einem K-Wert von 85 bisUmchlorid »ri4 100 g of benzyl alcohol dissolved. Stilled water is then made up to 10 liters 500 g of polyvinylpyrolidone with a K value of 85 to
95 (z. B. Kollidon· 90 d? >· Firma BASF) zugegeben und Beispiel 9 unter Rühren gelöst Zuletzt werden 1000 g LH-RH zugefügt und kalt gelöst Mit destilliertem Wasser wird auf 25 Zu 91 destilliertem Wasser werden 400 ml n-Essigsäu-10 laufgefüllt Die Lösung wird filtriert re, 282 ml η-Natronlauge, 50 g Natriumchlorid und95 (e.g. Kollidon 90 d?> From BASF) was added and Example 9 Dissolve with stirring Finally, 1000 g of LH-RH are added and dissolved in cold water. With distilled water to 25 to 91 of distilled water, 400 ml of n-acetic acid 10 are added The solution is filtered re, 282 ml of η-sodium hydroxide solution, 50 g of sodium chloride and
100 g Benzylalkohol gegeben. In dieser Mischung wer-Given 100 g of benzyl alcohol. In this mixture are
B eis pi el 2 den 10 g LH-RH-^cetat gelöst Es wird mit destilliertemExample pi el 2 the 10 g LH-RH- ^ acetate dissolved It is with distilled
Wasser auf 101 aufgefüllt Die Lösung wird filtriert Man verfährt nach Beispiel 1, verwendet jedoch anstelle von Polyvinylpyrrolidon Polyvinylalkohol mit einem K-Wert von ca. 90 (z. B. Mowiol® N 90-98 der Firma Hoechst).Water made up to 101. The solution is filtered The procedure of Example 1 is repeated, but instead of polyvinylpyrrolidone, polyvinyl alcohol with a K value of approx. 90 (e.g. Mowiol® N 90-98 from Hoechst).
91 destilliertes Wasser werden zum Sieden erhitzt und darin 20 g p-Hydroxybenzoesäuremethylester gelöst Man kühlt auf ca. 30° C ab, gibt 89,58 g Na2HPO4, 35,44 g Citronensäure, 10 g Natriumchlorid und 250 g Mannit zu und löst dann darin 10 g LH-RH auf. Man füllt mit destilliertem Wasser auf 101 auf und filtriert die Lösung.91 distilled water are heated to the boil and 20 g of p-hydroxybenzoic acid methyl ester are dissolved therein. The mixture is cooled to about 30 ° C., 89.58 g of Na 2 HPO 4 , 35.44 g of citric acid, 10 g of sodium chloride and 250 g of mannitol are added and then dissolves 10 g of LH-RH in it. It is made up to 101 with distilled water and the solution is filtered.
In 91 destilliertem Wasser von ca. 500C werden 50 g Methylcellulose mit einem Durchschnittssubstitutionsgrad von ca. 1,5 und einer Viskosität von 2700 bis 4000 cP (Tylose· MH 4000 ρ der Hoechst AG) suspendiert Man läßt die Suspension auf Raumtemperatur abkühlen. Dabei quillt die Methylcellulose auf. Dann wird eine Mischung aus 400 ml η-Essigsäure und 282 ml η-Natronlauge zugegeben, daraufhin 350 g Mannit, 500 mg Benzalkoniumchlorid und 5 g LH-RH gelöst und anschließend mit destilliertem Wasser auf 101 aufgefüllt Die Lösung wird filtriert50 g of methyl cellulose with an average degree of substitution of approx. 1.5 and a viscosity of 2700 to 4000 cP (Tylose · MH 4000 ρ from Hoechst AG) are suspended in 91% of distilled water at approx. 50 ° C. The suspension is allowed to cool to room temperature. The methyl cellulose swells in the process. Then a mixture of 400 ml η-acetic acid and 282 ml η-sodium hydroxide solution is added, then 350 g mannitol, 500 mg benzalkonium chloride and 5 g LH-RH are dissolved and then made up to 101 with distilled water. The solution is filtered
6060
Man verfährt nach Beispiel 4, verwendet jedoch anstelle der Methylcellulose Hydroxyäthylcellulose.The procedure of Example 4 is followed, but instead of methyl cellulose, hydroxyethyl cellulose is used.
6565
Man verfährt nach Beispiel 4, verwendet jedoch anstelle der Methylcellulose Hydroxypropylmethylcellulo-The procedure described in Example 4 is followed, but instead of the methyl cellulose, hydroxypropylmethyl cellulose is used.
Claims (2)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2254043A DE2254043C2 (en) | 1972-11-04 | 1972-11-04 | LH-releasing hormone for nasal application |
NL7314884A NL7314884A (en) | 1972-11-04 | 1973-10-30 | |
AT925073A AT329743B (en) | 1972-11-04 | 1973-11-02 | METHOD OF MANUFACTURING A PREPARATION FOR NASAL APPLICATION |
CA184,947A CA1014470A (en) | 1972-11-04 | 1973-11-02 | Lh-releasing hormone for nasal application |
ZA738459A ZA738459B (en) | 1972-11-04 | 1973-11-02 | Lh-releasing hormone for nasal application |
DK595973A DK137118C (en) | 1972-11-04 | 1973-11-02 | PROCEDURE FOR PREPARING AN LH-RH PREPARATION FOR NASA APPLICATION |
GB5132473A GB1454105A (en) | 1972-11-04 | 1973-11-05 | Preparation containing luteinizing hormone-releasing factor |
BE137402A BE806911A (en) | 1972-11-04 | 1973-11-05 | HORMONAL COMPOSITION RELEASING LIGHTENING HORMONE FOR NASAL APPLICATION AND ITS PREPARATION |
AU62158/73A AU486191B2 (en) | 1972-11-04 | 1973-11-05 | Lh-releasing hormone for nasal application |
FR7339240A FR2205308A1 (en) | 1972-11-04 | 1973-11-05 | Luteal hormone-releasing hormone prepns - for treatment of hypothalamus insufficiency by intranasal admin. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2254043A DE2254043C2 (en) | 1972-11-04 | 1972-11-04 | LH-releasing hormone for nasal application |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2254043A1 DE2254043A1 (en) | 1974-05-16 |
DE2254043C2 true DE2254043C2 (en) | 1985-01-24 |
Family
ID=5860826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2254043A Expired DE2254043C2 (en) | 1972-11-04 | 1972-11-04 | LH-releasing hormone for nasal application |
Country Status (8)
Country | Link |
---|---|
AT (1) | AT329743B (en) |
BE (1) | BE806911A (en) |
CA (1) | CA1014470A (en) |
DE (1) | DE2254043C2 (en) |
DK (1) | DK137118C (en) |
FR (1) | FR2205308A1 (en) |
NL (1) | NL7314884A (en) |
ZA (1) | ZA738459B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001185A1 (en) * | 1993-06-29 | 1995-01-12 | Ferring B.V. | Stabilized pharmaceutical peptide compositions |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59163313A (en) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
WO2004084859A2 (en) * | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3169095A (en) * | 1962-10-30 | 1965-02-09 | Rexall Drug Chemical | Self-propelling powder-dispensing compositions |
GB1230472A (en) * | 1967-07-10 | 1971-05-05 | ||
NL167323C (en) * | 1970-09-26 | 1981-12-16 | Organon Nv | PROCESS FOR PREPARING A PSYCHOPHARMACOLOGICAL PREPARATION. |
BE795516A (en) * | 1972-02-17 | 1973-08-16 | Ciba Geigy | PREPARATIONS OF OILY AND INJECTABLE PEPTIDES AND PROCESS FOR THEIR PREPARATION |
-
1972
- 1972-11-04 DE DE2254043A patent/DE2254043C2/en not_active Expired
-
1973
- 1973-10-30 NL NL7314884A patent/NL7314884A/xx not_active Application Discontinuation
- 1973-11-02 AT AT925073A patent/AT329743B/en not_active IP Right Cessation
- 1973-11-02 ZA ZA738459A patent/ZA738459B/en unknown
- 1973-11-02 CA CA184,947A patent/CA1014470A/en not_active Expired
- 1973-11-02 DK DK595973A patent/DK137118C/en not_active IP Right Cessation
- 1973-11-05 BE BE137402A patent/BE806911A/en not_active IP Right Cessation
- 1973-11-05 FR FR7339240A patent/FR2205308A1/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001185A1 (en) * | 1993-06-29 | 1995-01-12 | Ferring B.V. | Stabilized pharmaceutical peptide compositions |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
Also Published As
Publication number | Publication date |
---|---|
AU6215873A (en) | 1975-05-08 |
AT329743B (en) | 1976-05-25 |
ATA925073A (en) | 1975-08-15 |
CA1014470A (en) | 1977-07-26 |
NL7314884A (en) | 1974-05-07 |
DE2254043A1 (en) | 1974-05-16 |
DK137118C (en) | 1978-06-26 |
BE806911A (en) | 1974-05-06 |
DK137118B (en) | 1978-01-23 |
FR2205308B1 (en) | 1977-10-28 |
FR2205308A1 (en) | 1974-05-31 |
ZA738459B (en) | 1974-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69908326T2 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE DELAYED RELEASE OF PEPTIDES AND METHOD FOR THE PRODUCTION THEREOF | |
EP0339506B1 (en) | Oral osmotic system with a modified adhesion of the membrane to the core | |
DE3734835C2 (en) | Use of a substantially isotonic solution for the treatment and alleviation of eye diseases | |
DE3050131T1 (en) | IMPROVEMENTS TO METHODS FOR PREPARING GALENICAL PREPARATION WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENICAL PREPARATIONS FOR DRUGS OBTAINED THEREBY | |
DE69818026T2 (en) | AQUEOUS SUSPENSION FOR THE NASAL ADMINISTRATION OF LOTEPREDNOL | |
LU86966A1 (en) | ORALS THERAPEUTISCHES SYSTEM MIT SYSTEMISCHER WIRKUNG | |
DE1492015A1 (en) | Improved form of administration of pharmaceutical preparations | |
DE3827533A1 (en) | PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS | |
DE60103512T2 (en) | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED WITH MONOTHIOGLYCEROL, L-CYSTEIN OR THIOGLYCOLIC ACID | |
EP0185210B1 (en) | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis | |
DE2254043C2 (en) | LH-releasing hormone for nasal application | |
DE2323187A1 (en) | PROCESS FOR THE PRODUCTION OF A STABILIZED POWDERED SECRETIN PREPARATION BY FREEZE-DRYING | |
DE1915798C3 (en) | Antacid preparation in the form of an aqueous suspension | |
CH658787A5 (en) | PHARMACEUTICAL PREPARATIONS WITH UNIFORMING ELUTION PROPERTIES. | |
DE3538619A1 (en) | MEDICINAL PRODUCTS CONTAINING ISOMERS OF HYDROXYPROLIN | |
DE2243776C2 (en) | Complexes of tetracyclines with tris (hydroxymethyl) aminomethane, their preparation and medicinal products containing them | |
EP0277462A1 (en) | Process for the preparation of nasal solutions containing synthetic human calciton. | |
DE1915497C3 (en) | Medicinal products with hypolipidemic and hypocholesterolemic activity | |
DE2616748A1 (en) | INTESTINAL CAPSULES | |
AT401469B (en) | PHARMACEUTICAL AQUEOUS SOLUTION FOR PARENTERAL APPLICATION CONTAINING A SITU-COMPLEX OF AN ALKALOID WITH BIS-INDOL SCAFFOLDING AND METHOD FOR THE PRODUCTION THEREOF | |
DE60201117T2 (en) | Microgranules of ursodeoxycholic acid | |
WO2000056325A2 (en) | Ibuprofen solution | |
DE3208505A1 (en) | MEDIUM CONTAINING A LYOPHILIZED PENICILLINE DERIVATIVE | |
DD141996A1 (en) | METHOD FOR PRODUCING LYOPHILIZED LHRH PRAEPARATIONS | |
EP1021192B1 (en) | Dexamethasone gel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OD | Request for examination | ||
8125 | Change of the main classification | ||
D2 | Grant after examination | ||
8364 | No opposition during term of opposition |